Adding Regorafenib in First-Line ‘Promising’ in Gastric Cancer
Adding regorafenib (Stivarga) to a standard first-line chemoimmunotherapy…
Browsing Tag
FirstLine
Junshi Biosciences Announces Acceptance of the Supplemental New Drug Application for…
SHANGHAI, China, July 19, 2023 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences,” HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical…
Elevar Therapeutics Announces FDA Acceptance for Filing of New Drug Application for…
FORT LEE, N.J., July 17, 2023 (GLOBE NEWSWIRE) -- Elevar Therapeutics, Inc., a majority-owned subsidiary of HLB Co., Ltd., and a fully integrated biopharmaceutical company dedicated to…
A Changing Landscape in First-Line Endometrial Cancer
The buzz created by two phase III studies testing immunotherapy in advanced or recurrent…
PD-1 Inhibition in First-Line Prolongs Survival in Cervical Cancer
Updated findings of KEYNOTE-826, presented at the American Society of Clinical Oncology…
Looking at First-Line Options for Advanced Clear Cell Kidney Cancer
The first-line treatment options for advanced and metastatic clear cell renal cell carcinoma…
Including Polatuzumab Vedotin in First-Line DLBCL Treatment
The R-CHOP chemotherapy regimen -- rituximab (Rituxan), cyclophosphamide, doxorubicin,…
Studies Question Role of CDK4/6 Inhibitors in First-Line Advanced Breast Cancer
CHICAGO -- Upfront CDK4/6 inhibition or second-line use in advanced hormone receptor (HR)-positive/HER2-negative…
Pricey Drug Combo Boosts PFS in First-Line Advanced Ovarian Cancer
CHICAGO -- A three-drug combination significantly improved progression-free survival (PFS) in newly diagnosed…
Tempest to Report Early Results from Global Randomized Phase 1b/2 Combination Study…
<!-- Name:DistributionId Value:8827692 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->…